



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Daniele Generali
✉ dgeneral@units.it

RECEIVED 12 January 2024
ACCEPTED 15 January 2024
PUBLISHED 23 January 2024

CITATION

Generali D, Berardi R, Caruso M, Cazzaniga M, Garrone O, Minchella I, Paris I, Pinto C and De Placido S (2024) Corrigendum: Aromatase inhibitors: the journey from the state of the art to clinical open questions. *Front. Oncol.* 14:1369562. doi: 10.3389/fonc.2024.1369562

COPYRIGHT

© 2024 Generali, Berardi, Caruso, Cazzaniga, Garrone, Minchella, Paris, Pinto and De Placido. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Aromatase inhibitors: the journey from the state of the art to clinical open questions

Daniele Generali^{1,2*}, Rossana Berardi³, Michele Caruso⁴, Marina Cazzaniga^{5,6}, Ornella Garrone⁷, Ida Minchella⁸, Ida Paris⁹, Carmine Pinto¹⁰ and Sabino De Placido¹¹

¹Breast Cancer Unit, Azienda Socio Sanitaria Territoriale di Cremona, Cremona, Italy, ²Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy, ³Medical Oncology, Azienda Ospedaliera Universitaria (AOU) delle Marche, University Politecnica delle Marche, Ancona, Italy, ⁴Humanitas Istituto Clinico Catanese, Breast Centre Humanitas Catania, Catania, Italy, ⁵School of Medicine and Surgery University of Milano Bicocca, Milan, Italy, ⁶Phase 1 Research Unit, Azienda Socio Sanitaria Territoriale (ASST) Monza, Monza, Italy, ⁷Medical Oncology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, ⁸Division of Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy, ⁹Department of Woman and Child Health and Public Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy, ¹⁰Medical Oncology Unit, Comprehensive Cancer Centre, Azienda Unità Sanitaria Locale - Istituto di Ricerca e Cura a Carattere Scientifico (AUSL-IRCCS) di Reggio Emilia, Reggio Emilia, Italy, ¹¹Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy

KEYWORDS

aromatase inhibitors, bone loss, cardiotoxicity, drug adherence, breast cancer

A Corrigendum on

Aromatase inhibitors: the journey from the state of the art to clinical open questions

by Generali D, Berardi R, Caruso M, Cazzaniga M, Garrone O, Minchella I, Paris I, Pinto C and De Placido S (2023) *Front. Oncol.* 13:1249160. doi: 10.3389/fonc.2023.1249160

In the published article, there was an error in affiliation 8. Instead of “Division of Early Drug Development, European Institute of Oncology, Milan, Italy”, it should be “Division of Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.